2 recruiting, 1 active not recruiting, 1 completed, 1 terminated. 5 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Active not recruiting 1, Completed 1, Terminated 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02) Cyclophosphamid, Fludarabine, Interleukin 2 subcutaneous injection - Advanced NSCLC | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 24 | 2026-09-21 | 2026-10-14 |
| A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor HB0025, Pemetrexed, Paclitaxel - Advanced NSCLC, Advanced Endometrial Cancer | Phase 1 / Phase 2 | Recruiting | Huabo Biopharm Co., Ltd. | 282 | 2024-01-31 | 2025-01-23 |
| Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer REGN5093-M114, Cemiplimab - Advanced NSCLC | Phase 1 | Terminated | Regeneron Pharmaceuticals | 30 | 2021-11-09 | 2025-11-03 |
| Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC Nivolumab, Oxaliplatin, Ipilimumab - Advanced NSCLC | Phase 1 / Phase 2 | Active not recruiting | Hatim Husain | 30 | 2019-08-14 | 2025-05-28 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Squamous Cell (1) · Endometrial Neoplasms (1) · Recurrence (1)
Neoplasms (3) · Neoplasms by Site (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Carcinoma (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1)
Cyclophosphamide (2) · Nivolumab (2) · fludarabine (2) · Carboplatin (1) · Interleukin-2 (1) · Ipilimumab (1) · Oxaliplatin (1) · Paclitaxel (1) · Pemetrexed (1) · aldesleukin (1) · cemiplimab (1) · fludarabine phosphate (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · Hangzhou Huasai Biomedicine Co., Ltd. (1) · Hatim Husain (1) · Huabo Biopharm Co., Ltd. (1) · Regeneron Pharmaceuticals (1)
United States (3) · China (2)
Ben Creelan, M.D. (1) · Caicun Zhou, PhD. (1) · Hatim Husain (1) · Jundong Li, PhD. (1)